brukinsa
beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antinavikiniai vaistai - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).
litfulo
pfizer europe ma eeig - ritlecitinib tosilate - alopecia areata - imunosupresantai - litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.
clarithromycin ingen pharma
sia ingen pharma - klaritromicinas - plėvele dengtos tabletės - 250 mg; 500 mg - clarithromycin
ismn stada
stada arzneimittel ag - izosorbido mononitratas - tabletės - 20 mg; 40 mg - isosorbide mononitrate
nitromint
egis pharmaceuticals plc - glicerolio trinitratas - poliežuvinis purškalas - 400 µg/išpurškime; 2,6 mg - glyceryl trinitrate
sinomist
wick pharma - ksilometazolino hidrochloridas/dekspantenolis - nosies purškalas (tirpalas) - 0,5 mg/50 mg/ml; 1 mg/50 mg/ml - xylometazoline
xylometazoline/dexpanthenol teva
teva b.v. - ksilometazolino hidrochloridas/dekspantenolis - nosies purškalas (tirpalas) - 0,5 mg/50 mg/ml - xylometazoline
xylometazoline/dexpanthenol teva
teva b.v. - ksilometazolino hidrochloridas/dekspantenolis - nosies purškalas (tirpalas) - 1 mg/50 mg/ml - xylometazoline
theraflu
glaxosmithkline dungarvan limited - paracetamolis/fenilefrino hidrochloridas/gvajfenezinas - kietosios kapsulės - 1000 mg/12,2 mg/200 mg; 500 mg/6,1 mg/100 mg - paracetamol, combinations excl. psycholeptics
calquence
astrazeneca ab - acalabrutinib - leukemija, limfocitinė, lėtinė, b-ląstelė - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.